SCHEMBL26656390

SCHEMBL26656390

CC(=O)N1c2cc(S(N)(=O)=O)c(Br)cc2C[C@H]1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PKLR P30613 1/20 0.43
TNF P01375 4/20 0.42
NOD2 Q9HC29 4/20 0.42
NOD1 Q9Y239 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CA12 O43570 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32674253 0.86 PKLR (0.51) NOTUMGAAMAPTKDM4EMEN1
SCHEMBL26656315 0.85 NOTUM (0.47) NOTUMGAAMAPTKDM4EMEN1
SCHEMBL32673839 0.77 NOTUM (0.56) NOTUMMAPTPKLRTNFNOD2
SCHEMBL32673967 0.76 THRB (0.48) NOTUMMEN1KMT2APKLRTNF
SCHEMBL32673573 0.75 NOTUM (0.47) NOTUMMEN1KMT2APKLRTNF
SCHEMBL26080610 0.73 NOTUM (0.62) NOTUMGAAMAPTKDM4EMEN1
SCHEMBL26071790 0.73 NOTUM (0.62) NOTUMGAAMAPTKDM4EMEN1
SCHEMBL14058949 0.72 ACLY (0.53) NOTUMGAAKDM4EMEN1KMT2A
SCHEMBL26814093 0.70 POLB (0.39) GAAKMT2ATNFNOD2NOD1
SCHEMBL5798751 0.70 NOTUM (0.62) NOTUMGAAMAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522582-B2 Antiviral indolinyl compounds and uses thereof GILEAD SCIENCES, INC. (US) 2026-01-13 US disclosed
EP-4526289-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-03-26 EP disclosed
CN-119546574-A Antiviral indolinyl compounds and uses thereof 吉利德科学公司 2025-02-28 CN disclosed
US-20240101529-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2024-03-28 US disclosed
WO-2023225162-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-11-23 WO disclosed
WO-2023225162-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101529-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF MAVS, IRF3, EIF2AK2 NOTUM 1450/4885GAA 546/4885MAPT 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.